Search results
Results from the WOW.Com Content Network
Familial combined hyperlipidemia (FCH) is the familial occurrence of this disorder, probably caused by decreased LDL receptor and increased ApoB. Acquired combined hyperlipidemia is extremely common in patients who have other diseases from the metabolic syndrome ("syndrome X", incorporating diabetes mellitus type II , hypertension , central ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
Hyperlipidemia happens when you have high levels of one or more lipids in your blood. ... Dyslipidemia Treatment. Dyslipidemia treatments vary depending on which lipids are too high or too low ...
ADDING MULTIMEDIA: FDA Approves Merck's LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol LIPTRUZET Approved for Patients with Primary or ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. [1] It is a form of hyperlipidemia (high levels of lipids in the blood), hyperlipoproteinemia (high levels of lipoproteins in the blood), and dyslipidemia (any abnormalities of lipid and lipoprotein levels in the blood).
Mixed hyperlipidemia, in combination with fenofibrate; Homozygous familial hypercholesterolemia, in combination with specific statins; Homozygous sitosterolemia; A 2018 review found that ezetimibe used as sole treatment slightly lowered plasma levels of lipoprotein(a), but the effect was not large enough to be important. [22]
“With these older medications, the expectations for patients would be improving their cholesterol, blood glucose numbers or blood pressure,” Moreno told CNN by email this week.